ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcom...
ZyVersa Therapeutics, Inc. (ZVSA)
Company Research
Source: Yahoo! Finance
disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke. Cardiovascular complications are a leading cause of disability and death in people with T2DM. People with T2DM are 2 to 4 times more likely to experience cardiovascular events than people without T2DM, and post-event outcomes are often worse. About half of all diabetes-related fatalities can be attributed to cardiovascular causes. The published data provide evidence that inflammasome-induced inflammation plays a central role in the development and progression of T2DM and its cardiovascular complications by promoting insulin resistance, damage to the lining of blood vessels (endothelial dysfunction), and progression of plaque buildup in arteries. ZyVersa is developing Inflammasome ASC Inhibitor IC 100. Preclinical data demonstrate that IC 100 attenuates cardiometabolic conditions – it (1) decreased insulin resistance in a diabetic kidney disease model based on red
Show less
Read more
Impact Snapshot
Event Time:
ZVSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVSA alerts
High impacting ZyVersa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVSA
News
- ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- ZyVersa Therapeutics Reports Third Quarter 2025 Financial ResultsGlobeNewswire
- ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular OutcomesGlobeNewswire
ZVSA
Sec Filings
- 12/3/25 - Form 8-K
- 11/19/25 - Form 8-K
- 11/19/25 - Form 10-Q
- ZVSA's page on the SEC website